menu
    • menu

    Company profile for Amytrx Therapeutics

    NEW Drugs in Dev: 2
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amytrx TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    102 Woodmont Blvd | Suite 243 Nashville, TN 37205
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amytrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amytrx Therapeutics Welcomes Two Renowned Scientists to its Board of Directors
    Amytrx Therapeutics Welcomes Two Renowned Scientists to its Board of Directors

    07 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amytrx-therapeutics-welcomes-two-renowned-scientists-to-its-board-of-directors-301978879.html

    PR NEWSWIRE
    07 Nov 2023
    Share Share
    Amytrx Therapeutics' AMTX-100 Phase 1 Trial Data Presented at Conference
    Amytrx Therapeutics' AMTX-100 Phase 1 Trial Data Presented at Conference

    25 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amytrx-therapeutics-amtx-100-phase-1-clinical-trial-data-presented-at-revolutionizing-atopic-dermatitis-conference-301885634.html

    PR NEWSWIRE
    25 Jul 2023
    Share Share
    Amytrx Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3
    Amytrx Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3

    28 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

    PR NEWSWIRE
    28 Jun 2023
    Share Share
    Amytrx Tx Partners With AmbioPharm to Expand Anti-Inflammatory Peptides
    Amytrx Tx Partners With AmbioPharm to Expand Anti-Inflammatory Peptides

    27 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220726005016/en

    BUSINESSWIRE
    27 Jul 2022
    Share Share
    Amytrx's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
    Amytrx's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis

    09 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amytrx-therapeutics-amtx-100-cf3-moves-to-phase-ii-clinical-trial-for-atopic-dermatitis-301565077.html

    PRNEWSWIRE
    09 Jun 2022
    Share Share
    Highly secretive inflammation biotech secures final tranche of Series A round
    Highly secretive inflammation biotech secures final tranche of Series A round

    26 May 2022

    // Paul Schloesser ENDPTS

    https://endpts.com/two-years-post-stealth-exit-highly-secretive-inflammation-biotech-secures-final-tranche-of-series-a-round/

    Paul Schloesser ENDPTS
    26 May 2022
    Share Share

    ABOUT THIS PAGE

    Contact Amytrx Therapeutics and get a quotation

    Amytrx Therapeutics is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of AMTX-100 CF3 CMC bulk with DMF offered by Amytrx Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search